-$0.82 EPS Expected for Constellation Pharmaceuticals Inc (CNST) This Quarter
Equities research analysts expect Constellation Pharmaceuticals Inc (NASDAQ:CNST) to report earnings per share of ($0.82) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Constellation Pharmaceuticals’ earnings. The highest EPS estimate is ($0.71) and the lowest is ($0.88). The business is scheduled to issue its next earnings report on Thursday, February 14th.
On average, analysts expect that Constellation Pharmaceuticals will report full-year earnings of ($2.97) per share for the current financial year, with EPS estimates ranging from ($3.62) to ($2.63). For the next year, analysts anticipate that the business will report earnings of ($3.00) per share, with EPS estimates ranging from ($3.40) to ($2.51). Zacks’ EPS calculations are an average based on a survey of analysts that cover Constellation Pharmaceuticals.
Constellation Pharmaceuticals (NASDAQ:CNST) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.14).
Shares of Constellation Pharmaceuticals stock traded up $0.07 on Wednesday, reaching $5.85. The stock had a trading volume of 20,098 shares, compared to its average volume of 18,063. Constellation Pharmaceuticals has a fifty-two week low of $5.57 and a fifty-two week high of $12.21.
A number of large investors have recently added to or reduced their stakes in the stock. TRV GP LLC acquired a new position in Constellation Pharmaceuticals during the 3rd quarter valued at $20,419,000. FMR LLC acquired a new position in Constellation Pharmaceuticals during the 3rd quarter valued at $10,281,000. VHCP Management II LLC acquired a new position in Constellation Pharmaceuticals during the 3rd quarter valued at $4,891,000. EcoR1 Capital LLC acquired a new position in Constellation Pharmaceuticals during the 3rd quarter valued at $1,884,000. Finally, BlackRock Inc. acquired a new position in Constellation Pharmaceuticals during the 3rd quarter valued at $1,276,000. Hedge funds and other institutional investors own 22.70% of the company’s stock.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.